BioSpace News Archive

NantKwest, a leading clinical-stage, natural killer cell based therapeutics company, announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being held in New York City from June 4th-7th, 2019.

Neurotrope, Inc. announced that Dr. Daniel L. Alkon, the Company’s President and CSO, will speak in Session II. From News Headlines to Patients: Clinical Trial Ready Drugs.

DelMar Pharmaceuticals, Inc. announced that it entered into securities purchase agreements with certain institutional investors in connection with a registered direct offering of an aggregate of 1,170,000 shares of common stock and, in a concurrent private placement, warrants to purchase 760,500 shares of common stock.

Urges Shareholders to Vote “FOR” All the Board’s Qualified Nominees on the BLUE Proxy Card

Erchonia Corporation, global leader in the manufacturing and development of low-level lasers, has donated two of its high-tech lasers to Kent State Podiatry College to be used at the university and at the Cleveland Foot & Ankle Clinics.

Results Support Use of New Blood Test as Surrogate Endpoint in Clinical Trials Assessing Immune Checkpoint Inhibitor Effectiveness

Creating most comprehensive and cohesive body of clinical, health and demographic data to develop accurate snapshot of the national type 1 diabetes community

NeoImmuneTech, Inc., a T cell-focused immunotherapeutics company, announced the appointment of Samuel Zhang, Ph.D., M.B.A, as Chief Business Officer.

Panel to Feature Discussion About Creating a Winning Culture in the Biotech Industry

Top-line data from Phase II trial expected in second half 2020